{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:49:46Z","timestamp":1770353386446,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["1604\/00123"],"award-info":[{"award-number":["1604\/00123"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["1604\/00122"],"award-info":[{"award-number":["1604\/00122"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["1604\/00122"],"award-info":[{"award-number":["1604\/00122"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["1604\/00122"],"award-info":[{"award-number":["1604\/00122"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["1604\/00123"],"award-info":[{"award-number":["1604\/00123"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutic mRNA delivery has been described for several treatment options, such as vaccination and cancer immunotherapy. However, mRNA delivery has to be accompanied by the development and testing of suitable carrier materials due to the instability of mRNAs in human body fluids. In the present study, we investigated the ability of recently developed Viromers to deliver mRNAs in a classical inflammatory setting. We tested mRNAs coding for active components of preclinical (7ND) and approved (sTNF-RII) biologics, in vitro and in vivo. 7ND is an established blocker of the CCR2 axis, whereas sTNF-RII is the active component of the approved drug Etanercept. Viromer\/mRNA complexes were transfected into murine macrophages in vitro. Protein expression was analysed using Luciferase reporter expression and mainly identified in spleen, blood and bone marrow in vivo. 7ND-mRNA delivery led to efficient blockage of monocytes infiltration in thioglycolate-induced peritonitis in mice, underlining the ability of Viromers to deliver a therapeutic mRNA cargo without overt toxicity. Therefore, we propose Viromer-based mRNA delivery as a suitable option for the treatment of inflammatory disorders beyond infusion of biological molecules.<\/jats:p>","DOI":"10.1038\/s41598-020-72004-8","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T10:03:33Z","timestamp":1600164213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Viromers as carriers for mRNA-mediated expression of therapeutic molecules under inflammatory conditions"],"prefix":"10.1038","volume":"10","author":[{"given":"Edith","family":"Jansig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Kuenemund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hietel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Wussow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Kreideweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Panzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reinsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Cynis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"72004_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland, L. W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141\u2013147 (1997).","journal-title":"N. Engl. J. Med."},{"key":"72004_CR2","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s12325-014-0149-1","volume":"31","author":"M Marziniak","year":"2014","unstructured":"Marziniak, M. & Meuth, S. Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis. Adv. ther. 31, 915\u2013931 (2014).","journal-title":"Adv. ther."},{"key":"72004_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0167-7799(99)01416-X","volume":"18","author":"A Mountain","year":"2000","unstructured":"Mountain, A. Gene therapy: the first decade. Trends Biotechnol. 18, 119\u2013128 (2000).","journal-title":"Trends Biotechnol."},{"key":"72004_CR4","doi-asserted-by":"publisher","first-page":"1306-8","DOI":"10.1007\/s001080170052","volume":"42","author":"M Hallek","year":"2001","unstructured":"Hallek, M. et al. Grundlagen der Gentherapie. Prinzipien und Stand der Entwicklung. Der Internist 42, 1306-8-1311\u20138 (2001).","journal-title":"Der Internist"},{"key":"72004_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6. mRNA-based therapeutics: developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"72004_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"72004_CR7","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1073\/pnas.0608582104","volume":"104","author":"T Cedervall","year":"2007","unstructured":"Cedervall, T. et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. 104, 2050\u20132055 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"72004_CR8","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/s41467-018-07654-4","volume":"9","author":"A Fiore","year":"2018","unstructured":"Fiore, A. et al. Induction of immunosuppressive functions and NF-\u03baB by FLIP in monocytes. Nat Commun. 9, 5193 (2018).","journal-title":"Nat Commun."},{"key":"72004_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.4049\/jimmunol.1800924","volume":"202","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. Exploitation of synthetic mRNA to drive immune effector cell recruitment and functional reprogramming in vivo. J. Immunol. (Baltim. Md. 1950) 202, 608\u2013617 (2019).","journal-title":"J. Immunol. (Baltim. Md. 1950)"},{"key":"72004_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/gen.34.04.12","volume":"34","author":"S Panzner","year":"2014","unstructured":"Panzner, S. Transfection: viral and synthetic techniques converge. Gen. Eng. Biotechnol. News 34, 20\u201321 (2014).","journal-title":"Gen. Eng. Biotechnol. News"},{"key":"72004_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/458624","author":"S Rao","year":"2015","unstructured":"Rao, S., Morales, A. A. & Pearse, D. D. The comparative utility of Viromer RED and lipofectamine for transient gene introduction into glial cells. BioMed Res. Int. https:\/\/doi.org\/10.1155\/2015\/458624 (2015).","journal-title":"BioMed Res. Int."},{"key":"72004_CR12","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1096\/fj.02-0094fje","volume":"16","author":"M Usui","year":"2002","unstructured":"Usui, M. et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J. 16, 1838\u20131840 (2002).","journal-title":"FASEB J."},{"key":"72004_CR13","doi-asserted-by":"crossref","first-page":"15918","DOI":"10.1016\/S0021-9258(17)40768-X","volume":"269","author":"YJ Zhang","year":"1994","unstructured":"Zhang, Y. J., Rutledge, B. J. & Rollins, B. J. Structure\/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte. J. Biol. Chem. 269, 15918\u201315924 (1994).","journal-title":"J. Biol. Chem."},{"key":"72004_CR14","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/MCB.15.9.4851","volume":"15","author":"Y Zhang","year":"1995","unstructured":"Zhang, Y. & Rollins, B. J. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol. Cell Biol. 15, 4851\u20134855 (1995).","journal-title":"Mol. Cell Biol."},{"key":"72004_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1084\/jem.186.1.131","volume":"186","author":"JH Gong","year":"1997","unstructured":"Gong, J. H., Ratkay, L. G., Waterfield, J. D. & Clark-Lewis, I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. 186, 131\u2013137 (1997).","journal-title":"J. Exp. Med."},{"key":"72004_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1084\/jem.181.2.631","volume":"181","author":"JH Gong","year":"1995","unstructured":"Gong, J. H. & Clark-Lewis, I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J. Exp. Med. 181, 631\u2013640 (1995).","journal-title":"J. Exp. Med."},{"key":"72004_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1097-2765(00)80139-2","volume":"2","author":"L Gu","year":"1998","unstructured":"Gu, L. et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2, 275\u2013281 (1998).","journal-title":"Mol. Cell"},{"key":"72004_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/emmm.201100158","volume":"3","author":"H Cynis","year":"2011","unstructured":"Cynis, H. et al. The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol. Med. 3, 545\u2013558. https:\/\/doi.org\/10.1002\/emmm.201100158 (2011).","journal-title":"EMBO Mol. Med."},{"key":"72004_CR19","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.4049\/jimmunol.0802812","volume":"183","author":"M Takahashi","year":"2009","unstructured":"Takahashi, M., Galligan, C., Tessarollo, L. & Yoshimura, T. Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary chemokine required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A. J. Immunol. 183, 3463\u20133471. https:\/\/doi.org\/10.4049\/jimmunol.0802812 (2009).","journal-title":"J. Immunol."},{"key":"72004_CR20","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","volume":"10","author":"M Maugeri","year":"2019","unstructured":"Maugeri, M. et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat. Commun. 10, 4333 (2019).","journal-title":"Nat. Commun."},{"key":"72004_CR21","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1038\/mtna.2014.61","volume":"3","author":"V Kumar","year":"2014","unstructured":"Kumar, V. et al. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol. Ther. Nucleic Acids 3, e210 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"72004_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210\u20131216 (2012).","journal-title":"Nat. Biotechnol."},{"key":"72004_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/JVI.01786-15","volume":"90","author":"M Brazzoli","year":"2016","unstructured":"Brazzoli, M. et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J. Virol. 90, 332\u2013344. https:\/\/doi.org\/10.1128\/JVI.01786-15 (2016).","journal-title":"J. Virol."},{"key":"72004_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1172\/JCI0214364","volume":"109","author":"A Heiser","year":"2002","unstructured":"Heiser, A. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Investig. 109, 409\u2013417 (2002).","journal-title":"J. Clin. Investig."},{"key":"72004_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/mt.2012.250","volume":"21","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol. Ther. J. Am. Soc. Gene Ther. 21, 358\u2013367 (2013).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"72004_CR26","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/sj.gt.3301220","volume":"7","author":"V Schirmacher","year":"2000","unstructured":"Schirmacher, V. et al. Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. Gene Ther. 7, 1137\u20131147 (2000).","journal-title":"Gene Ther."},{"key":"72004_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2119\/molmed.2012.00339","volume":"19","author":"Z Liu","year":"2013","unstructured":"Liu, Z. et al. The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites. Mol. Med. 19, 276\u2013285. https:\/\/doi.org\/10.2119\/molmed.2012.00339 (2013).","journal-title":"Mol. Med."},{"key":"72004_CR28","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1161\/01.CIR.0000018603.67989.71","volume":"105","author":"E Mori","year":"2002","unstructured":"Mori, E. et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 105, 2905\u20132910 (2002).","journal-title":"Circulation"},{"key":"72004_CR29","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1161\/01.CIR.103.16.2096","volume":"103","author":"W Ni","year":"2001","unstructured":"Ni, W. et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103, 2096\u20132101 (2001).","journal-title":"Circulation"},{"key":"72004_CR30","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/01.ASN.0000120371.09769.80","volume":"15","author":"T Wada","year":"2004","unstructured":"Wada, T. et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am. Soc. Nephrol. 15, 940\u2013948 (2004).","journal-title":"J Am. Soc. Nephrol."},{"issue":"Suppl 1","key":"72004_CR31","doi-asserted-by":"publisher","first-page":"i46","DOI":"10.1136\/ard.59.suppl_1.i46","volume":"59","author":"G Spencer-Green","year":"2000","unstructured":"Spencer-Green, G. Etanercept (Enbrel): update on therapeutic use. Ann. Rheum. Dis. 59(Suppl 1), i46\u2013i49 (2000).","journal-title":"Ann. Rheum. Dis."},{"key":"72004_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease, P. J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385\u2013390 (2000).","journal-title":"Lancet"},{"key":"72004_CR33","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1681\/ASN.V7112379","volume":"7","author":"J Tekstra","year":"1996","unstructured":"Tekstra, J. et al. Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. J. Am. Soc. Nephrol. 7, 2379\u20132384 (1996).","journal-title":"J. Am. Soc. Nephrol."},{"key":"72004_CR34","first-page":"1876","volume":"142","author":"N Topley","year":"1993","unstructured":"Topley, N. et al. Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha. Am. J. Pathol. 142, 1876\u20131886 (1993).","journal-title":"Am. J. Pathol."},{"key":"72004_CR35","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0002-9440(10)64095-3","volume":"158","author":"J Witowski","year":"2001","unstructured":"Witowski, J. et al. Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: induction by macrophage-derived cytokines. Am. J. Pathol. 158, 1441\u20131450 (2001).","journal-title":"Am. J. Pathol."},{"key":"72004_CR36","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.4049\/jimmunol.163.11.6148","volume":"163","author":"A Matsukawa","year":"1999","unstructured":"Matsukawa, A. et al. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J. Immunol. 163, 6148\u20136154 (1999).","journal-title":"J. Immunol."},{"key":"72004_CR37","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar1914","volume":"8","author":"MC Montesinos","year":"2006","unstructured":"Montesinos, M. C., Desai, A. & Cronstein, B. N. Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthr. Res. Ther. 8, R53 (2006).","journal-title":"Arthr. Res. Ther."},{"key":"72004_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2217\/17435889.1.3.297","volume":"1","author":"ML Immordino","year":"2006","unstructured":"Immordino, M. L., Dosio, F. & Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1, 297\u2013315 (2006).","journal-title":"Int. J. Nanomed."},{"key":"72004_CR39","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1073\/pnas.0334864100","volume":"100","author":"AE Proudfoot","year":"2003","unstructured":"Proudfoot, A. E. et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA 100, 1885\u20131890 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72004_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrd3048","volume":"9","author":"RR Koenen","year":"2010","unstructured":"Koenen, R. R. & Weber, C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat. Rev. Drug Discov. 9, 141\u2013153. https:\/\/doi.org\/10.1038\/nrd3048 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"72004_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/protein\/gzs008","volume":"25","author":"IC Severin","year":"2012","unstructured":"Severin, I. C. et al. Properties of 7ND-CCL2 are modulated upon fusion to Fc. Protein Eng. Des. Sel. PEDS 25, 213\u2013222 (2012).","journal-title":"Protein Eng. Des. Sel. PEDS"},{"key":"72004_CR42","doi-asserted-by":"publisher","first-page":"17s","DOI":"10.1200\/JOP.2017.026062","volume":"13","author":"RD Harvey","year":"2017","unstructured":"Harvey, R. D. Science of biosimilars. J. Oncol. Pract. 13, 17s\u201323s (2017).","journal-title":"J. Oncol. Pract."},{"key":"72004_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-1-4939-6481-9_13","volume":"1499","author":"T Hinz","year":"2017","unstructured":"Hinz, T. et al. The European regulatory environment of RNA-based vaccines. Methods Mol. Biol. (Clifton N.J.) 1499, 203\u2013222 (2017).","journal-title":"Methods Mol. Biol. (Clifton N.J.)"},{"key":"72004_CR44","doi-asserted-by":"publisher","first-page":"8196","DOI":"10.1074\/jbc.M114.602748","volume":"290","author":"M Manchekar","year":"2015","unstructured":"Manchekar, M., Liu, Y., Sun, Z., Richardson, P. E. & Dashti, N. Phospholipid transfer protein plays a major role in the initiation of apolipoprotein B-containing lipoprotein assembly in mouse primary hepatocytes. J. Biol. Chem. 290, 8196\u20138205 (2015).","journal-title":"J. Biol. Chem."},{"key":"72004_CR45","first-page":"221","volume":"33","author":"H Pertoft","year":"1980","unstructured":"Pertoft, H., Johnsson, A., W\u00e4rmeg\u00e5rd, B. & Seljelid, R. Separation of human monocytes on density gradients of Percoll. J. Immunol. Methods 33, 221\u2013229 (1980).","journal-title":"J. Immunol. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72004-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T10:22:08Z","timestamp":1696674128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72004"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72004-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"23 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors PK, SP and CR are employees of BioNTech Delivery Technologies GmbH, Halle, Germany. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15090"}}